The Phase III SUMMIT trial showed that tirzepatide significantly reduces the risk of worsening heart failure events or death from cardiovascular causes, enhances physical function, and leads to weight loss and reduced inflammation in patients with heart failure with preserved ejection fraction.
In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, highlights how stakeholders can best support sites throughout complex studies.
With universal adoption of health literacy best practices slow going over the years, advocates are redefining the term to encompass much more of what health-related communication requires beyond simply words.
Multiple Phase III trials and open label extensions show Bimzelx (bimekizumab-bkzx) offers an effective approach in targeting key inflammatory pathways involved in psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.
What learning science has taught us about the drivers and predictors of change—and applying those to clinical research practice.
Phase III DREAMM-7 trial data show that the combination of Blenrep (belantamab mafodotin) with bortezomib and dexamethasone (BorDex) significantly improved overall survival in patients with relapsed or refractory multiple myeloma compared to standard treatment with Darzalex (daratumumab) and BorDex.
In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, discusses the differences between working with local labs and central labs.
Over 200 stakeholders highlighted challenges such as communication, training, and improving technology.
Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.
In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, touches on how therapeutic area can affect which labs a sponsor decides to work with.
Results from survey of 100 site personnel suggest a disconnect is present between these stakeholders.
The current lack of clinical trial professionals is a serious concern that's compromising the ability to conduct high-quality clinical trials, but it's not irreversible.
In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, highlights best practices for data standardization and consistency.
How industry can increase the speed of these trials while continuing to meet patient needs.
Phase III COMBI-AD trial final analysis shows that 12 months of adjuvant therapy with Tafinlar (dabrafenib) and Mekinist (trametinib) in patients with resected stage III melanoma significantly improved relapse-free survival and distant metastasis-free survival compared to placebo.
In this video interview, Kelli Aufderheide, director, laboratory decentralized trial solutions, IQVIA Laboratories, discusses the different types of labs in clinical research and what they offer.
The approval is based on results from the admIRE study, which showed 100% of atrial fibrillation patients achieved acute procedural success.
Phase III WAYPOINT trial found that Tezspire (tezepelumab-ekko) effectively reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with nasal polyps, offering a promising new treatment option with a consistent safety profile.
In the first part of this roundtable discussion, a panel of experts introduce themselves and highlight the challenges industry is seeing with underrepresentation of racial and ethnic groups in clinical trials.
Two-part study will evaluate the safety and tolerability of ZW191 in solid tumors across a variety of cancers including ovarian and endometrial.
An interim analysis of the Phase III ALIGN trial found that 36 weeks of treatment with atrasentan significantly reduced proteinuria in high-risk IgA nephropathy patients with a favorable safety profile, supporting its potential role in managing the disease.
In this video interview, Jay Park, founder & scientific lead, Core Clinical Sciences, discusses how risk-based monitoring can alert sponsors of falling short of enrollment goals.
Trial data over 30 days showed the novel Intravascular Lithotripsy catheter safely modified calcium, enabling effective treatment.
The STEP 9 trial found that once-weekly semaglutide significantly reduced knee osteoarthritis pain and body weight in patients with obesity, improved physical function, and potentially reduced the need for NSAIDs and opioids.
In this video interview, Rebecca Metcalfe, principal scientist, patient-centered research, Core Clinical Sciences, highlights the consequences of focusing solely on enrollment targets.
An overview of key trends in communication, logistical preferences, and demographic influences that shape patient engagement and retention in clinical trials.
In this video interview, Jay Park, founder & scientific lead; and Rebecca Metcalfe, principal scientist, patient-centered research; both with Core Clinical Sciences, share their reactions to the FDA releasing its Diversity Action Plan Guidance.
Results showed significantly improved social functioning and quality of life across three different doses.
In this video interview, Jay Park, founder & scientific lead; and Rebecca Metcalfe, principal scientist, patient-centered research; both with Core Clinical Sciences, discuss a recent article they authored on the guidance.
A post hoc analysis of the SELECT trial shows semaglutide 2.4 mg significantly reduced hospital admissions and hospital stay lengths in adults with obesity or overweight and cardiovascular disease but without diabetes.
